August 2012
-
Rein Therapeutics announced that the FDA has lifted a full clinical hold on the Phase 2 “RENEW” trial of the company’s LTI-03 inhaled dry powder caveolin-1-based peptide in patients with idiopathic pulmonary fibrosis (IPF). The… Read more . . .
-
Iconovo, which said earlier this year that it would discontinue internal development and would focus on commercialization of its existing DPI platforms, has announced that CEO Johan Wäborg will step down, and advisor Anders Månsson… Read more . . .
-
Ritedose Corporation announced that it licensed an ANDA for tobramycin inhalation solution from Hikma and that the FDA has approved the company to manufacture and distribute the product. The company noted that tobramycin, which is… Read more . . .
-
Padagis has announced a $36 million expansion of its manufacturing facilities in Minneapolis, MN, USA, specifically highlighting the new capacity to manufacture naloxone nasal spray in the US. According to the company, “The additional capabilities… Read more . . .
-
The 2025 edition of the Drug Delivery to the Lungs (DDL) meeting is once again expected to draw approximately 1,100 inhaled and nasal drug delivery experts to the Edinburgh International Conference Centre (EICC). The conference,… Read more . . .
-
According to Amneal Pharmaceuticals, the FDA has tentatively approved Amneal’s ANDA for a generic of Teva’s QVAR beclomethasone dipropionate HFA MDI, 40 μg/actuation and 80 μg/actuation, for the treatment of asthma. The company notes that… Read more . . .
-
ENA Respiratory has announced the closing of a $22.4 million Series B financing, including a previously announced $5 million investment from the Flu Lab and participation by the Gates Foundation. The proceeds will be used… Read more . . .
-
Tonix Pharmaceuticals announced that Massachusetts General Hospital has initiated a Phase 1 trial called FOCUS to evaluate Tonix’s TNX-1900 and TNX-2900 oxytocin nasal sprays in patients with arginine-vasopressin deficiency (central diabetes insipidus). The FOCUS study… Read more . . .
-
GSK has announced that a Phase 3 trial comparing an HFA-152a formulation of Ventolin salbutamol (albuterol) MDI to the currently marketed HFA-134a formulation demonstrated therapeutic equivalence. The company also said that safety of the LGWP propellant… Read more . . .
-
OINDP specialist CDMO Kenox Pharmaceuticals has announced the appointment of Julianne Berry as VP of R&D and Manufacturing. Berry was most recently VP, Respiratory Product Development at Odin Pharmaceuticals and has extensive experience in the development of inhaled… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland